Hernix40 mg

Hernix is an oral, irreversible tyrosine kinase inhibitor used in the treatment of HER2-positive breast cancer. It is prescribed and monitored by an oncology specialist. Approved (established) indications include:

• Extended adjuvant treatment (FDA-approved): Hernix is indicated for the extended adjuvant treatment of adult patients with early-stage HER2-positive breast cancer, to follow prior adjuvant trastuzumab-based therapy.
• Advanced/metastatic disease, combination therapy (FDA-approved): In combination with capecitabine, Hernix is indicated for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens in the metastatic setting.

Hernix is not used as monotherapy for metastatic disease and has no established role outside HER2-positive breast cancer. It should only be initiated and supervised by a physician experienced in the use of anticancer therapy.

Each film-coated tablet contains Neratinib (as neratinib maleate) 40 mg as the active ingredient, along with pharmaceutically accepted excipients used for tablet formulation (fillers, binders, disintegrants, lubricants, and film-coating agents).

Hernix is a small-molecule, orally administered tyrosine kinase inhibitor developed for the treatment of HER2-positive breast cancer. It belongs to the class of pan-HER (ErbB family) tyrosine kinase inhibitors and works by irreversibly binding to and inactivating key growth-signalling receptors on cancer cells.

Hernix is supplied as an oral film-coated tablet and is taken once daily with food as part of a specialist-supervised cancer treatment plan. Because of its side-effect profile, particularly severe diarrhea, treatment with Hernix requires mandatory preventive measures and close monitoring during the initial period of therapy.

Hernix belongs to the therapeutic class of antineoplastic agents, specifically oral tyrosine kinase inhibitors (targeted anti-HER2 therapy). It falls within the broader category of protein kinase inhibitors used in oncology.

Neratinib is an irreversible inhibitor of the tyrosine kinase activity associated with HER1 (EGFR), HER2, and HER4 receptors. By covalently binding to these receptors, Neratinib blocks downstream signal transduction pathways (including the RAS-MAPK and PI3K-AKT pathways) that promote tumour cell proliferation and survival.

In HER2-overexpressing breast cancer cells, this irreversible pan-HER blockade by Neratinib reduces receptor-driven signalling, leading to inhibition of tumour cell growth and induction of apoptosis in preclinical models.

Pharmacokinetics

• Absorption: Oral bioavailability is increased with food; gastric acid-reducing agents (e.g. proton pump inhibitors) significantly reduce absorption of Neratinib.
• Metabolism: Extensively metabolized in the liver, primarily via CYP3A4, with minor contribution from flavin-containing monooxygenase.
• Elimination: Predominantly excreted in feces, with an elimination half-life of approximately 7 to 17 hours; steady state is reached within about 7-8 days of once-daily dosing.

Hernix tablets should be taken orally, once daily, with food, at approximately the same time each day to maintain consistent blood levels. Tablets should be swallowed whole with water and should not be chewed, crushed, or split.

Concomitant use of proton pump inhibitors should be avoided during treatment with Hernix, as they substantially reduce its absorption (see Drug Interactions). If gastric-acid suppression is required, alternatives should be timed appropriately and discussed with the prescribing physician.

Hernix is a substrate of CYP3A4 and P-glycoprotein, making it susceptible to clinically significant drug interactions:

• Proton pump inhibitors (e.g. omeprazole): Significantly reduce absorption and plasma levels of Hernix by raising gastric pH; concomitant use should be avoided.
• H2-receptor antagonists (e.g. ranitidine, famotidine): Reduce absorption of Hernix; if unavoidable, dosing should be separated (H2 blocker taken 10 hours before or 2 hours after Hernix).
• Antacids: Should be taken at least 3 hours before or after Hernix to minimize reduced absorption.
• Strong or moderate CYP3A4 inhibitors (e.g. ketoconazole, clarithromycin, certain grapefruit products): Increase plasma concentrations of Hernix and the risk of toxicity (especially diarrhea and hepatotoxicity); concomitant use should be avoided.
• Strong or moderate CYP3A4 inducers (e.g. rifampin, carbamazepine, phenytoin, St. John's Wort): May significantly reduce plasma concentrations and efficacy of Hernix; concomitant use should be avoided.
• P-glycoprotein substrates with narrow therapeutic index (e.g. digoxin): Hernix may increase plasma concentrations of these drugs; monitor closely if co-administered.

The most common adverse reaction with Hernix is diarrhea, which occurs in the large majority of patients and can be severe if not managed with prophylactic antidiarrheal therapy (see Precautions and Warnings).

Very common (may affect more than 1 in 10 people)

• Diarrhea (including severe cases)
• Nausea and vomiting
• Abdominal pain
• Fatigue
• Rash
• Stomatitis (mouth sores)
• Decreased appetite
• Muscle spasms
• Weight loss, dehydration

Common (may affect up to 1 in 10 people)

• Elevated liver enzymes
• Dry skin, nail disorders
• Urinary tract infection
• Electrolyte disturbances related to diarrhea/dehydration

Patients experiencing severe or persistent diarrhea, signs of dehydration, jaundice, or unusual fatigue while taking Hernix should contact their treating physician promptly.

Pregnancy: Based on its mechanism of action and animal reproduction data, Hernix can cause fetal harm when administered to a pregnant woman. Hernix should be used during pregnancy only if clearly needed and the potential benefit justifies the potential risk to the fetus; a physician must be consulted before use. Women of reproductive potential should use effective contraception during treatment with Hernix and for at least one month after the final dose, and pregnancy should be avoided during this period. Male patients with female partners of reproductive potential should also use effective contraception.

Lactation: It is not known whether Hernix passes into human breast milk. Because of the potential for serious adverse reactions in a breastfed infant, breastfeeding is not recommended during treatment with Hernix and for at least one month after the final dose; a physician should be consulted regarding infant feeding options.

Diarrhea (most significant risk): Diarrhea is very common with Hernix and can be severe, leading to dehydration, electrolyte imbalance, renal impairment, and hospitalization. Mandatory antidiarrheal prophylaxis (typically with loperamide, per a structured titration schedule) is required starting with the first dose of Hernix and continuing through at least the first treatment cycle, as directed by the treating oncologist. Adequate hydration should be maintained, and dose interruption, reduction, or discontinuation of Hernix may be required for severe or persistent diarrhea despite optimal antidiarrheal management.

Hepatotoxicity: Elevations in liver enzymes have been reported with Hernix. Liver function tests should be monitored monthly for the first 3 months of treatment, then periodically thereafter and as clinically indicated. Dose modification or discontinuation may be required for significant hepatic transaminase elevations.

Embryo-fetal toxicity: See Pregnancy and Lactation. Effective contraception is required during and after treatment with Hernix as described above.

General: Hernix should only be prescribed and monitored by a physician experienced in the management of anticancer therapy. Patients should be counselled on the importance of antidiarrheal prophylaxis, adherence, and prompt reporting of gastrointestinal or hepatic symptoms.

There is limited clinical experience with overdose of Hernix. Overdose would be expected to worsen known adverse effects, particularly severe diarrhea, dehydration, and liver enzyme abnormalities. There is no specific antidote for Hernix overdose. In case of suspected overdose, seek immediate medical attention or contact emergency services/a poison control center; supportive care and monitoring of hydration status and liver function should be provided under medical supervision.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Hepatic impairment: No dose adjustment is needed for mild-to-moderate hepatic impairment. In severe hepatic impairment (Child-Pugh Class C), the starting dose of Hernix should be reduced to 80 mg once daily.

Renal impairment: No specific dose adjustment is established; available data suggest no clinically significant effect of renal function on exposure, but severe renal impairment has not been well studied and caution is advised.

Elderly patients: Limited data are available in patients over 65 years of age; no overall differences in safety or effectiveness have been clearly established, but this population should be monitored closely for tolerability.

Pediatric patients: See Pediatric Uses below.

For extended adjuvant treatment of early-stage HER2-positive breast cancer, Hernix is typically administered continuously for one year, unless disease recurrence, unacceptable toxicity, or physician-directed discontinuation occurs. In combination with capecitabine for advanced/metastatic disease, Hernix is continued in repeated 21-day cycles for as long as clinical benefit is observed and toxicity remains manageable, as determined by the treating oncologist.

Neratinib belongs to the drug class of tyrosine kinase inhibitors, specifically the pan-HER (ErbB family) inhibitors used as targeted antineoplastic (anticancer) agents.

Neratinib irreversibly binds to the intracellular tyrosine kinase domains of HER1 (EGFR), HER2, and HER4 receptors, covalently inactivating their kinase activity. This blocks receptor autophosphorylation and downstream activation of the RAS-MAPK and PI3K-AKT signalling pathways that drive proliferation and survival of HER2-overexpressing tumour cells, resulting in inhibition of tumour growth.

The safety and effectiveness of Hernix in pediatric patients have not been established. Hernix is indicated only for adult patients with HER2-positive breast cancer and is not recommended for use in children or adolescents.